SCHEMBL3758865

SCHEMBL3758865

CC[C@]1(C#N)[C@H]2C[C@H]2[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 6/20 0.53
ALDH1A1 P00352 3/20 0.53
NR3C1 P04150 3/20 0.53
PGR P06401 2/20 0.53
ADRA1A P35348 1/20 0.53
HTR2B P41595 1/20 0.53
CYP17A1 P05093 1/20 0.52
LMNA P02545 5/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
CYP19A1 P11511 5/20 0.52
SERPINA6 P08185 5/20 0.52
HSD17B10 Q99714 4/20 0.52
BLM P54132 4/20 0.52
PMP22 Q01453 3/20 0.52
TSHR P16473 3/20 0.52
CYP2C19 P33261 3/20 0.52
HIF1A Q16665 2/20 0.52
CYP3A4 P08684 1/20 0.52
MAPK1 P28482 2/20 0.51
HSD17B3 P37058 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3746809 0.93 SHBG (0.54) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3750353 0.88 SHBG (0.49) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3746811 0.85 SHBG (0.53) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3754138 0.85 SHBG (0.57) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3746531 0.85 SHBG (0.57) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3748862 0.84 SHBG (0.54) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3751402 0.84 SHBG (0.54) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3753711 0.81 SHBG (0.50) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL9128191 0.80 SHBG (0.68) SHBGALDH1A1NR3C1PGRADRA1A
SCHEMBL3744652 0.80 SHBG (0.58) SHBGALDH1A1NR3C1PGRADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE BAYER SCHERING PHARMA AG (DE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292184-A1 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE HSD17B11, HSD17B7, NR5A1 SHBG 24/4885ALDH1A1 1039/4885NR3C1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.